Traws Pharma, Inc.
TRAW
$1.88
$0.021.08%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 4,694.74% | 1.79% | 0.00% | 0.00% | 0.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4,694.74% | 1.79% | 0.00% | 0.00% | 0.00% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 4,694.74% | 1.79% | 0.00% | 0.00% | 0.00% |
| SG&A Expenses | -14.47% | -17.94% | 66.79% | 29.56% | -10.58% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -32.97% | -0.15% | 18.06% | 66.98% | 27.30% |
| Operating Income | 78.77% | 0.17% | -18.29% | -67.73% | -27.64% |
| Income Before Tax | 99.26% | 531.27% | -615.15% | -78.84% | -2,797.48% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 99.26% | 531.27% | -615.15% | -78.84% | -2,797.48% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 99.26% | 531.27% | -615.15% | -78.84% | -2,797.48% |
| EBIT | 78.77% | 0.17% | -18.29% | -67.73% | -27.64% |
| EBITDA | 78.78% | 0.12% | -18.35% | -67.86% | -27.66% |
| EPS Basic | 99.48% | 113.07% | 634.44% | -56.25% | -305.16% |
| Normalized Basic EPS | 97.20% | 152.11% | -95.19% | -56.25% | -10.76% |
| EPS Diluted | 99.46% | 112.62% | 634.44% | -56.25% | -305.18% |
| Normalized Diluted EPS | 97.20% | 150.31% | -95.19% | -56.25% | -10.76% |
| Average Basic Shares Outstanding | 474.96% | 727.60% | 266.38% | 14.45% | 20.64% |
| Average Diluted Shares Outstanding | 474.96% | 757.21% | 266.38% | 14.45% | 20.64% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |